LCM
KRBP

Lynwood Capital Management’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Lynwood Capital Management’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,000
Closed -$256K – 162
2022
Q1 		$256K Sell
10,000
-2,417
-19% -$71.5K 0.27% 73
2021
Q4 		$570K Buy
+12,417
New +$846K 0.55% 53

Other funds holding KRBP

ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lynwood Capital Management's KRBP Position: Q2 2022 in Review

Lynwood Capital Management sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q2 2022, closing a stake of 10,000 shares — an estimated $256K sold.

Lynwood Capital Management first reported a position in KRBP in Q4 2021 and held it in 2 quarters. The position peaked at $570K in Q4 2021. 17 funds tracked by Wall St. Rank hold KRBP as of Q2 2022.

  • Lynwood Capital Management reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Lynwood Capital Management sold 10,000 Kiromic BioPharma, Inc. Common Stock shares in Q2 2022, an estimated $256K.
  • Lynwood Capital Management first reported a position in Kiromic BioPharma, Inc. Common Stock in Q4 2021 and held it in 2 quarters.
  • Lynwood Capital Management's Kiromic BioPharma, Inc. Common Stock position peaked at $570K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q2 2022.

Based on Lynwood Capital Management's 13F filing for Q2 2022, filed 2 Aug 2022.